GENE ONLINE|News &
Opinion
Blog

2017-11-01| Asia-Pacific

October 31, 2001: Genomic Sequence of a Specific Strain of Filamentous Cyanobacterium Anabaena sp. was Completed

by GeneOnline
Share To

The complete genomic sequence of a filamentous cyanobacterium, Anabaena sp. strain PCC 7120, was completed by an internatioanl team led by Takakazu Kaneko, Japanese microbiologist. The result was published in October, 2001, and revealed a total of 5368 potential protein-encoding genes in its chromosome. Among the whole genome, 28% of the protein-encoding genes sequenced were not found in the exist public DNA databases at that time. Anabaena is an important bacteria in agricuture for its nitrogen-fixing ability. The revelation of its genomic sequence helped scientists to study the genes related to nitrogen fixation and to select bacteria with strong nitrogen-fixing ability, which might help reducing the usage of chemical fertilizer.

 

Reference

https://dnaresearch.oxfordjournals.org/content/8/5/205.abstract

Image Source

https://en.wikipedia.org/wiki/Anabaena

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
How Single Cell Sequencing is Advancing Biomedical Research
2022-07-15
Researchers Have Now Identified the Complete Human Genome without Any Gaps
2022-04-06
M&A
Sema4 Buys GeneDx in Bid to Expand Genomic Database and Testing
2022-01-19
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top